| Segment Reporting – Corporate and Other/Merck Group | ||||||
|
|
|
|
|
| ||
|
|
Corporate and Other |
Merck Group | ||||
|
EUR million |
Q1 |
Q1 |
Q1 |
Q1 | ||
| ||||||
|
Sales |
– |
– |
2,477.5 |
2,022.8 | ||
|
Royalty, license and commission income |
– |
– |
86.2 |
76.1 | ||
|
Total revenues |
– |
– |
2,563.8 |
2,098.9 | ||
|
Gross margin |
– |
– |
1,924.1 |
1,612.2 | ||
|
Marketing and selling expenses |
–0.5 |
–1.1 |
–591.6 |
–468.2 | ||
|
Royalty, license and commission expenses |
– |
– |
–111.3 |
–122.2 | ||
|
Administration expenses |
–19.5 |
–16.3 |
–124.9 |
–104.4 | ||
|
Other operating expenses and income |
–5.3 |
–34.2 |
–97.1 |
–134.9 | ||
|
Research and development |
– |
0.1 |
–379.5 |
–347.2 | ||
|
Operating result |
–25.3 |
–51.5 |
371.6 |
294.8 | ||
|
Exceptional items |
– |
– |
158.0 |
– | ||
|
Earnings before interest and tax (EBIT) |
–25.3 |
–51.5 |
529.5 |
294.8 | ||
|
Net operating assets* |
66.8 |
74.7 |
17,856.6 |
18,470.5 | ||
|
Segment liabilities* |
–11.7 |
–14.9 |
–1,787.9 |
–1,898.4 | ||
|
Capital spending on property, plant and equipment |
0.1 |
0.1 |
74.9 |
64.7 | ||
|
Investments in intangible assets |
2.4 |
0.9 |
9.3 |
14.0 | ||
|
Depreciation and amortization |
–1.5 |
–0.6 |
–302.5 |
–220.2 | ||
|
Impairment losses |
– |
– |
–50.4 |
–26.2 | ||
|
Net cash flows from operating activities |
252.1 |
–111.8 |
284.9 |
278.7 | ||
|
Net cash flows from investing activities |
259.9 |
1,344.8 |
104.3 |
1,269.5 | ||
|
Free cash flow |
255.9 |
–120.4 |
645.3 |
194.8 | ||
|
Underlying free cash flow |
255.9 |
–108.6 |
185.6 |
206.6 | ||
|
FCR in % |
– |
– |
7.2 |
9.8 | ||
|
ROS in % |
– |
– |
14.5 |
14.0 | ||